Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568497 | 1.00 | OPRD1 (0.49) | OPRD1KMT2AALDH1A1HPGDOPRM1 | |
| SCHEMBL6699164 | 0.86 | KMT2A (0.47) | OPRD1KMT2AALDH1A1HPGDOPRM1 | |
| SCHEMBL6693686 | 0.86 | KMT2A (0.49) | OPRD1KMT2AALDH1A1HPGDOPRM1 | |
| SCHEMBL5567749 | 0.86 | KMT2A (0.57) | OPRD1KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL6698122 | 0.86 | KMT2A (0.51) | OPRD1KMT2AALDH1A1HPGDOPRM1 | |
| SCHEMBL6701730 | 0.86 | KMT2A (0.48) | OPRD1KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL6700031 | 0.85 | KMT2A (0.46) | OPRD1KMT2AALDH1A1HPGDOPRM1 | |
| SCHEMBL6695105 | 0.85 | MAPT (0.54) | OPRD1KMT2AALDH1A1HPGDMAOB | |
| SCHEMBL6877172 | 0.84 | OPRD1 (0.47) | OPRD1KMT2AALDH1A1HPGDOPRM1 | |
| SCHEMBL29968962 | 0.84 | OPRD1 (0.47) | OPRD1KMT2AALDH1A1HPGDOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |